Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.
Dong C, Wu J, Chen Y, Nie J, Chen C. · 2021
Read Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. by Dong C, Wu J, Chen Y, Nie J, Chen C. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8005514.txt.
Introduction
Dong and co-authors review how switching on the PI3K/AKT/mTOR signaling pathway helps breast cancer resist treatment. Chemotherapy, targeted drugs, and hormone therapy cut recurrence for many patients. Yet many tumors adapt and stop responding. The authors link that failure to overactive pathway signaling, which also drives cancer growth and spread.
The review maps the pathway's role in resistance across the main breast cancer types. It surveys drugs built to block PI3K, AKT, or mTOR. Many are now in clinical trials, paired with standard therapies. The authors weigh strategies for beating acquired resistance. They also propose a plan for developing new drugs against the pathway.
Catalog record
| CREATOR | Dong C, Wu J, Chen Y, Nie J, Chen C. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer By Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen Published in: Frontiers in Pharmacology DOI: 10.3389/fphar.2021.628690 ABSTRACT Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer. INTRODUCTION Breast cancer is the leading cause of cancer death in women around the world (Siegel and Miller, 2020). At the molecular level, breast cancer is a heterogeneous disease, divided into hormone/estrogen-receptor-positive (HR+/ER+), human epidermal growth factor receptor-2-positive (HER2+) and ER/PR/HER2 triple-negative breast cancer (TNBC) with corresponding treatment strategies according to molecular subtypes (Nagini, 2017). Common treatments include endocrine therapy (ET) for HR+ disease, HER2 targeted therapy for HER2+ disease, chemotherapy, and immunotherapy for TNBC patients as well as PARP inhibitors for BRCA-mutated TNBC patients. Acquired resistance leads to tumor relapse in breast cancer, which is associated with multiple but relatively independent mechanisms, including overexpression of breast cancer resistance protein (BCRP, also called ABCG2), modification of cell cycle checkpoints, inhibition of apoptosis, and activation of multiple signaling pathways (Kartal-Yandim et al., 2016). The PI3K/AKT/mTOR pathway has emerged as a novel target for overcoming drug resistance in recent years (Keegan et al., 2018; Verret et al., 2019). Dysregulation of this pathway is closely related to tumor progression and resistance to standard therapies in breast cancer (Guerrero-Zotano et al., 2016). The PI3K/AKT/mTOR pathway is one of the most frequently activated pathways in several types of cancers (Alzahrani, 2019). This is also one of the most important reasons for intrinsic resistance. Several drugs against the PI3K/AKT/mTOR pathway are in clinical development. In this review, we summarize the current knowledge of the PI3K/AKT/mTOR pathway related to drug resistance in breast cancer and propose an effective drug development strategy. PI3K/AKT/MTOR PATHWAY AND THEIR INHIBITORS PI3K/AKT/mTOR Pathway The PIK3CA gene is one of the most frequently mutated genes in breast cancer (Mukohara, 2015), which leads to PI3K activation and serves as a key determinant of standard anticancer therapy resistance (Liu, et al., 2019; Luo, et al., 2018; Qiu, et al., 2019). The PI3K protein belongs to a large family of lipid kinases, classified into three classes on the basis of different structures and functions. Among them, class I PI3Ks, the most fully studied heterodimers, consist of a p110 catalytic subunit and a p85 regulatory subunit, which play a predominant role in many cancers (Dornan and Burke, 2018). The PI3K protein has the dual activities of serine/threonine (Ser/Thr) kinase and phosphatidylinositol kinase and is activated in two ways: by interacting with various growth factor receptors, such as epithelial growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), and by recruiting an adaptor protein to promote the binding of p110 and p85 to activate PI3K. Activated PI3K can convert phosphatidylinositol 3,4-bisphosphate (PIP2) into 3,4,5-triphosphate (PIP3), PIP3 serves as the second messenger which can bind to phosphoinositide-dependent kinase-1 (PDK1) to phosphorylate AKT at Thr308. AKT can also be phosphorylated by mTORC2 at Ser473 (Figure 1). AKT is the key signal transduction protein that phosphorylates several substrates and downstream effectors, including mTOR, matrix metalloproteinase (MMP), cyclin-dependent kinases (CDKs), and VEGF (Liu et al., 2009; Cidado and Park, 2012) (Figure 1). [Figure: PI3K/AKT signaling pathway in breast cancer. EGF(R): epidermal growth factor (receptor); PI3K: phosphatidylinositol 3-kinase; PDK1/2: 3-phosphoinositide dependent kinase-1/2; mTOR: mammalian target of rapamycin; NF-κB: nuclear factor kappa-B; MMP9: matrix metallo protein 9; VEGF: vascular endothelial growth factor.] PI3K/AKT/mTOR Inhibitors To date, several PI3K inhibitors (PI3Ki), including alpelisib, idelalisib and copanlisib, have been approved by the Food and Drug Administration (FDA) (Janku et al., 2018) in many types of cancer. According to the targeted isoforms of class IA PI3Ks, PI3Ki can be classified into pan-PI3Ki, such as buparlisib (BKM120) and pictilisib (GDC-0941), isoform-specific PI3Ki, such as taselisib (GDC-0032) and alpelisib (BYL719), and dual mTOR/pan PI3Ki, such as BEZ235. BYL719 is the first oral PI3Ki that targets the p110α isoform selectively (IC50 = 4.6 nM) (Fritsch et al., 2014), and it was the first approved PI3K inhibitor combined with fulvestrant for patients with HR+/HER2− metastatic breast cancer (mBC) along with PIK3CA mutations that have progressed on or after endocrine-based regimens (Markham, 2019). Taselisib is another oral class I isoform-specific PI3K inhibitor, as it exhibits equal inhibition of p110α, p110γ and p110δ (Ndubaku et al., 2013). Buparlisib, an oral pan-PI3K inhibitor, targets all four isoforms of class I PI3K (Hu et al., 2015). Pictilisib (GDC-0941) is another oral pan-PI3K inhibitor that shows equipotent efficiency in inhibiting the p110α and p110δ isoforms in vitro (Martín et al., 2017). Based on previous results of clinical trials, compared to pan-PI3K inhibitors, these isoform-specific PI3K inhibitors show improved tolerability and increased anticancer efficacy (Krop et al., 2016; Baselga et al., 2017; André et al., 2019); thus, more selective PI3K inhibitors are expected in the future. According to the structure and the binding site, AKT inhibitors (AKTi) can be divided into PH domain inhibitors: allosteric inhibitors and ATP competitive inhibitors. Several PH domain inhibitors and allosteric inhibitors were terminated in the preclinical stage due to poor pharmacokinetic properties and heavy toxicity effects. The current research hotspot is ATP competitive inhibitors such as ipatasertib (GDC-0068) and capivasertib (AZD-5363). As a downstream molecule of the PI3K/AKT pathway, mTOR inhibitors can inhibit breast cancer cell growth. Everolimus was the first approved mTOR inhibitor for HR+/HER2− breast cancer and showed an improved PFS in several clinical trials (Bachelot et al., 2012; Yardley et al., 2013), whereas another mTOR inhibitor, temsirolimus, showed only moderate activity in HR+ breast cancer patients with age ≤ 65 years, but this randomized phase III trial was terminated for futility as total PFS was not improved by temsirolimus plus letrozole as first-line therapy, so the best suitable population for temsirolimus needs to be further identified (Wolff et al., 2013). Detailed information on these PI3K/AKT/mTOR inhibitors is listed in Table 1. [Table: Summary clinical RCT trials of PI3K/AKT/mTOR inhibitors in breast cancer.] In addition, activation of the PI3K/AKT pathway can upregulate multidrug resistance-associated protein-1 (MRP1), ABCG2 and P-glycoprotein (P-gp, also called ABCB1) expression, which could be involved in multidrug resistance (Tazzari et al., 2007; Wang et al., 2016a). Dysregulation of the PI3K/AKT pathway has an impact on resistance to chemotherapy, endocrine therapy, HER2− targeted therapy, PARP inhibitors, and immunotherapy in breast cancer, and blockage of this pathway can enhance drug sensitivity and reverse resistance (Miller et al., 2011a; Hu et al., 2015; Pernas and Tolaney, 2019). Overall, accumulated evidence suggests that PI3K/AKT inhibitors could combine with other anticancer therapies to overcome drug resistance in breast cancer. PI3K/AKT/MTOR PATHWAY INDUCES DRUG RESISTANCE IN BREAST CANCER PI3K/AKT/mTOR Pathway in Endocrine Therapy-Resistant Breast Cancer Several types of endocrine drugs, including selective ER modulators (tamoxifen), aromatase inhibitors (AIs, such as letrozole and exemestane),